LUCD Stock Price, Lucid Diagnostics Inc. Quote, Chart

Market Summary

USD0.91+0.02

Delayed

2.25%

LUCD Stock Price

View Fullscreen

LUCD RSI Chart

LUCD Valuation

Market Cap

47.4M

Price/Earnings (Trailing)

-1.01

Price/Sales (Trailing)

15.9

EV/EBITDA

-0.51

Price/Free Cashflow

-1.24

LUCD Price/Sales (Trailing)

LUCD Profitability

Operating Margin

80.39%

EBT Margin

-1576.63%

Return on Equity

-395.42%

Return on Assets

-146.75%

Free Cashflow Yield

-80.9%

LUCD Fundamentals

LUCD Revenue

Revenue (TTM)

3.0M

Rev. Growth (Yr)

124.44%

Rev. Growth (Qtr)

-3.75%

LUCD Earnings

Earnings (TTM)

-47.0M

Earnings Growth (Yr)

34.68%

Earnings Growth (Qtr)

2.01%

Breaking Down LUCD Revenue

Last 7 days

-3.2%

Last 30 days

13.8%

Last 90 days

-33.1%

Trailing 12 Months

-42.4%

How does LUCD drawdown profile look like?

LUCD Financial Health

Current Ratio

1.38

LUCD Investor Care

Shares Dilution (1Y)

19.18%

Diluted EPS (TTM)

-1.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.0M	0	0	0
2023	634.0K	793.0K	1.5M	2.4M
2022	533.0K	481.0K	429.0K	377.0K
2021	0	0	0	585.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lucid Diagnostics Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 07, 2024	gordon michael adam	acquired	-	-	400,000	general counsel and secretary
May 07, 2024	o'neil shaun	acquired	-	-	400,000	president and coo
May 07, 2024	aklog lishan	acquired	-	-	400,000	chief executive officer
May 07, 2024	mcgrath dennis m	acquired	-	-	400,000	chief financial officer
Feb 15, 2024	pavmed inc.	sold	-	-	-3,331,750	-
Jan 26, 2024	pavmed inc.	acquired	4,675,470	1.4033	3,331,770	-
Sep 26, 2023	lapidus stanley	sold	-43,173	1.45134	-29,747	-
Sep 25, 2023	lapidus stanley	sold	-286	1.43	-200	-
Sep 21, 2023	lapidus stanley	sold	-144	1.44	-100	-

Which funds bought or sold LUCD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	888	81,412	98,818	-%
May 15, 2024	Royal Bank of Canada	reduced	-55.05	-	-	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-1.14	-18,060	23,731	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	sold off	-100	-190,350	-	-%
May 15, 2024	LUMINUS MANAGEMENT LLC	reduced	-7.19	-509,047	581,230	0.26%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-50.00	-289,867	132,281	0.01%
May 15, 2024	Tower Research Capital LLC (TRC)	added	1,867	14,747	16,178	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-78.57	-17.00	3.00	-%
May 15, 2024	MORGAN STANLEY	added	388	508	790	-%
May 15, 2024	STATE STREET CORP	added	75.15	90.00	14,925	-%

Are Funds Buying or Selling LUCD?

Are funds buying LUCD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LUCD

No. of Funds

Unveiling Lucid Diagnostics Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 20, 2024	pavmed inc.	65.2%	31,302,444	SC 13D/A
Feb 14, 2024	ayrton capital llc	9.9%	1,163,629	SC 13G
Feb 02, 2024	pavmed inc.	72.2%	34,634,191	SC 13D/A
Mar 24, 2023	ayrton capital llc	4.87%	2,222,222	SC 13G/A
Mar 23, 2023	ayrton capital llc	9.99%	4,816,167	SC 13G
Dec 02, 2022	pavmed inc.	73.7%	31,302,420	SC 13D/A

Recent SEC filings of Lucid Diagnostics Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 13, 2024	10-Q	Quarterly Report
May 09, 2024	3	Insider Trading
May 09, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 07, 2024	8-K	Current Report
May 02, 2024	8-K	Current Report

Peers (Alternatives to Lucid Diagnostics Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Lucid Diagnostics Inc. News

Latest updates

Lucid Diagnostics Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)											(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-3.7%	1,001,000	1,040,000	783,000	159,000	446,000	112,000	76,000	-	189,000	166,500	144,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	369,000	-	144,273
Gross Profit	-	-	-	-	-	-	112,000	76,000	-	-180,000	-	200,000
Operating Expenses	-5.6%	11,793,000	12,493,000	11,911,000	11,743,000	14,763,000	15,087,000	14,453,000	14,628,000	12,460,000	11,540,500	6,710,000
S&GA Expenses	-4.9%	4,194,000	4,408,000	3,837,000	4,032,000	4,127,000	5,013,000	3,930,000	3,873,000	3,318,000	2,632,500	918,000
R&D Expenses	-12.9%	1,501,000	1,723,000	1,615,000	1,827,000	2,282,000	2,337,000	2,704,000	3,440,000	2,881,000	3,481,500	2,190,000
EBITDA Margin	27.6%	-14.83	-20.49	-36.18	-68.66	-90.88	-143	-117	-90.99	-67.56	-46.86	-
Interest Expenses	9.1%	12,000	11,000	149,000	223,000	33,000	-	-	-	-	-	447,000
Earnings Before Taxes	2.0%	-10,612,000	-10,830,000	-14,208,000	-11,381,000	-16,247,000	-14,928,000	-14,349,000	-14,624,000	-12,270,000	-11,305,500	-6,957,000
EBT Margin	27.3%	-15.77	-21.69	-37.84	-71.76	-94.87	-148	-122	-93.88	-68.85	-48.00	-
Net Income	2.0%	-10,612,000	-10,830,000	-14,208,000	-11,381,000	-16,247,000	-14,928,000	-14,349,000	-14,624,000	-12,270,000	-11,305,500	-6,957,000
Net Income Margin	27.3%	-15.77	-21.69	-37.84	-71.76	-94.87	-148	-122	-93.88	-68.85	-48.00	-
Free Cashflow	-26.6%	-12,629,000	-9,979,000	-8,798,000	-7,029,000	-7,062,000	-4,258,000	-7,346,000	-15,357,000	-5,924,000	-10,701,000	-2,210,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	17.5%	32.00	27.00	33.00	42.00	49.00	33.00	38.00	45.00	62.00	59.00	3.00	2.00
Current Assets	25.0%	28.00	22.00	27.00	36.00	42.00	24.00	30.00	36.00	52.00	57.00	3.00	1.00
Cash Equivalents	31.1%	25.00	19.00	24.00	33.00	40.00	22.00	27.00	33.00	48.00	54.00	0.00	0.00
Inventory	47.5%	0.00	0.00	-	-	-	0.00	-	-	-	-	-	-
Net PPE	-6.9%	1.00	1.00	1.00	1.00	2.00	2.00	1.00	1.00	1.00	1.00	-	-
Liabilities	-31.9%	20.00	30.00	31.00	27.00	24.00	9.00	11.00	9.00	16.00	4.00	27.00	16.00
Current Liabilities	-32.0%	20.00	29.00	30.00	27.00	23.00	8.00	10.00	8.00	14.00	4.00	-	-
Shareholder's Equity	614.7%	12.00	-2.31	3.00	15.00	25.00	23.00	28.00	36.00	46.00	55.00	-	-
Retained Earnings	-12.0%	-168	-150	-139	-125	-114	-98.07	-83.15	-68.80	-54.17	-41.90	-30.60	-13.83
Additional Paid-In Capital	5.1%	136	130	129	127	126	121	111	105	101	97.00	6.00	0.00
Shares Outstanding	14.0%	48.00	42.00	42.00	42.00	42.00	41.00	36.00	35.00	35.00	35.00	14.00	14.00
Float	-	-	-	-	14.00	-	-	-	19.00	-	-	81.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-26.6%	-12,612	-9,962	-8,781	-7,012	-7,045	-4,258	-6,346	-13,305	-5,776	-9,877	-2,182	-2,294	-3,315	-	-
Share Based Compensation	-0.7%	743	748	1,032	1,165	2,817	3,488	3,280	3,554	3,537	-	-	-	-	-	-
Cashflow From Investing	78.9%	-37.00	-175	-14.00	-15.00	-17.00	-203	-1,321	-2,436	-148	-824	-28.00	-1.00	-9.00	-	-
Cashflow From Financing	270.4%	18,522	5,000	275	75.00	24,110	1.00	1,922	501	187	64,336	-	4,439	3,300	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LUCD Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Income Statement [Abstract]

Revenue

$ 1,001

$ 446

Operating expenses:

Cost of revenue

1,656

1,338

Sales and marketing

4,194

4,127

General and administrative

4,070

6,900

Amortization of acquired intangible assets

372

505

Research and development

1,501

1,893

Total operating expenses

11,793

14,763

Operating loss

(10,792)

(14,317)

Other income (expense):

Interest income

68

78

Interest expense

(12)

(33)

Change in fair value - Senior Secured Convertible Note

291

(789)

Loss on issue and offering costs - Senior Secured Convertible Note

(1,186)

Debt extinguishments loss - Senior Secured Convertible Note

(167)

Other income (expense), net

180

(1,930)

Loss before provision for income tax

(10,612)

(16,247)

Provision for income taxes

Net loss attributable to Lucid Diagnostics Inc.

(10,612)

(16,247)

Less: Deemed dividend on Series A and Series A-1 Convertible Preferred Stock

(7,496)

Net loss attributable to Lucid Diagnostics Inc. common stockholders

$ (18,108)

$ (16,247)

Net loss per share - basic

^[1]

$ (0.40)

Net loss per share - diluted

^[1]

$ (0.40)

Weighted average common shares outstanding, basic

45,014,410

40,970,504

Weighted average common shares outstanding, diluted

45,014,410

40,970,504

[1]

- Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.

LUCD Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 24,769	$ 18,896
Accounts receivable	49	45
Inventory	410	278
Prepaid expenses, deposits, and other current assets	2,355	2,854
Total current assets	27,583	22,073
Fixed assets, net	1,242	1,334
Operating lease right-of-use assets	1,039	1,307
Intangible assets, net	1,052	1,424
Other assets	1,132	1,132
Total assets	32,048	27,270
Current liabilities:
Accounts payable	969	1,146
Accrued expenses and other current liabilities	3,136	3,841
Operating lease liabilities, current portion	861	1,106
Senior Secured Convertible Note - at fair value	13,140	13,950
Due To: PAVmed Inc. - MSA Fee and operating expenses	1,871	9,339
Total current liabilities	19,977	29,382
Operating lease liabilities, less current portion	177	199
Total liabilities	20,154	29,581
Commitments and contingencies
Stockholders’ Equity:
Preferred stock, $0.001 par value, 20,000,000 shares authorized; Series B Convertible Preferred Stock, issued and outstanding 44,285 at March 31, 2024 and Series A and Series A-1 Convertible Preferred Stock, shares issued and outstanding 18,625 at December 31, 2023	44,285	18,625
Common stock, $0.001 par value, 200,000,000 shares authorized; 46,747,062 and 42,329,864 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	47	42
Additional paid-in capital	136,411	129,763
Accumulated deficit	(168,849)	(150,741)
Total Stockholders’ Equity (Deficit)	11,894	(2,311)
Total Liabilities and Stockholders’ Equity (Deficit)	$ 32,048	$ 27,270

About Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

0

CEO	Dr. Lishan Aklog M.D.
WEBSITE	luciddx.com
INDUSTRY	Medical Instruments & Supplies

Lucid Diagnostics Inc. Frequently Asked Questions

What is the ticker symbol for Lucid Diagnostics Inc.? What does LUCD stand for in stocks?

LUCD is the stock ticker symbol of Lucid Diagnostics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lucid Diagnostics Inc. (LUCD)?

As of Fri May 17 2024, market cap of Lucid Diagnostics Inc. is 47.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LUCD stock?

You can check LUCD's fair value in chart for subscribers.

What is the fair value of LUCD stock?

You can check LUCD's fair value in chart for subscribers. The fair value of Lucid Diagnostics Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lucid Diagnostics Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LUCD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lucid Diagnostics Inc. a good stock to buy?

The fair value guage provides a quick view whether LUCD is over valued or under valued. Whether Lucid Diagnostics Inc. is cheap or expensive depends on the assumptions which impact Lucid Diagnostics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LUCD.

What is Lucid Diagnostics Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LUCD's PE ratio (Price to Earnings) is -1.01 and Price to Sales (PS) ratio is 15.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LUCD PE ratio will change depending on the future growth rate expectations of investors.